Skip to main content
Clinical Trials/NCT00052481
NCT00052481
Completed
Not Applicable

Health-Related Quality Of Life In Patients With Low Risk, Localized Prostate Cancer Randomized To Radical Prostatectomy Or Brachytherapy

Alliance for Clinical Trials in Oncology13 sites in 1 country500 target enrollmentSeptember 2002
ConditionsProstate Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Alliance for Clinical Trials in Oncology
Enrollment
500
Locations
13
Primary Endpoint
time to treatment failure
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy.

PURPOSE: Randomized clinical trial to study quality of life in patients undergoing radical prostatectomy or brachytherapy for stage II prostate cancer.

Detailed Description

OBJECTIVES: * Compare changes in health-related quality of life (HRQOL) in patients with stage II prostate cancer up to 2 years after treatment with radical prostatectomy or brachytherapy. * Compare the effect of baseline HRQOL, age, and other covariates on HRQOL improvement or deterioration in these patients up to 10 years after these treatments. * Compare the effect of treatment modality on HRQOL improvement or deterioration in these patients up to 10 years after these treatments. * Compare the effects of treatment failure on HRQOL, in terms of disease progression, in these patients. OUTLINE: Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy). Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment. PROJECTED ACCRUAL: A total of 500 patients (250 per group) will be accrued for this study within 2 years.

Registry
clinicaltrials.gov
Start Date
September 2002
End Date
April 2004
Last Updated
9 years ago
Study Type
Observational
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

time to treatment failure

Time Frame: Up to 10 years

Secondary Outcomes

  • disease progression(Up to 10 years)

Study Sites (13)

Loading locations...

Similar Trials